Михаил Дмитриевич Нуждин

Михаил Дмитриевич Нуждин

Auto-generated profile, based on publicly available information

Михаил Дмитриевич Нуждин

Chelyabinsk Regional Clinical Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
MNMikhail D. Nuzhdin
Mikhail D. Nuzhdin
RKRoman N. Komarov
Roman N. Komarov
DMDenis A. Matsuganov
Denis A. Matsuganov
NNNikita B. Nadtochiy
Nikita B. Nadtochiy

30 June 2024 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
RKRoman Komarov
Roman Komarov
DMDenis A. Matsuganov
Denis A. Matsuganov
DBDmitry O. Bystrov
Dmitry O. Bystrov
МНМихаил Дмитриевич Нуждин
Михаил Дмитриевич Нуждин
HighlightsAF recurrence is a common complication of AF surgical treatment. This complication is influenced by a large number of factors. In this article, we propose a model that allows specialists to predict this complication in patients at high risk.  AbstractAim. To identify predictors associated with a high risk of atrial fibrillation in patients with sinus rhythm following mitral valve surgery.Methods. The surgical treatment outcomes of 36 patients with mitral valve disease and sinus rhythm who underwent mitral valve surgery from 2013 to 2018 were analyzed.Results. We have developed a prognostic model describing the risk of atrial fibrillation depending on the impact of risk factors. The presence atrial flutter before surgery increases the risk of developing AF by 9.06 times, an increase in left ventricle end-systolic size by 1 centimeter increases the risk by 20.12 times, an increase in the right atrium size by 1 centimeter increases the risk by 14.99 times, and the need for temporary cardiac pacing in the early postoperative period increases the risk by 14.47 times.Conclusion. The proposed prognostic model can be used to select patients at high risk of developing AF after mitral valve surgery with sinus rhythm for prophylactic ablation.

3 April 2024
Verified
Book Chapter
Open access
PDF file
MNMikhail D. Nuzhdin
Mikhail D. Nuzhdin
RKRoman N. Komarov
Roman N. Komarov
VBVladimir A. Bolsunovsky
Vladimir A. Bolsunovsky
Symptomatic tricuspid valve diseases are associated with a high risk of heart failure and poor prognosis. The current valve substitutes still carry the risk of associated complications. Allografts have been considered a valuable surgical option for decades since the first reports were introduced. The challenging surgical technique along with controversial results and homograft shortage discourage surgical society from wider use of allografts in tricuspid surgery. The largest world surgical experience with mitral allograft in the treatment of tricuspid valve disease is described in the study. A total of 20 patients underwent tricuspid valve replacement by mitral homograft in two clinics from October 2021 to February 2023. Surgical technique and initial results are presented in the chapter. There was no early mortality, postoperative bleeding, myocardium infarction, stroke, or sternal wound infection. Two patients needed permanent pacemaker implantation after redoing surgery before discharge. In the follow-up period, two patients suffered from a relapse of infective endocarditis in 3 and 6 months postoperatively with moderate homograft dysfunction, none of them underwent reintervention. There was no late mortality or permanent pacemaker implantation in the follow-up period. Satisfactory clinical and hemodynamic results, reproduceable technique and accessibility make homografts plausible valve substitutes in tricuspid surgery.

25 June 2023 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
RKRoman Komarov
Roman Komarov
МНМихаил Дмитриевич Нуждин
Михаил Дмитриевич Нуждин
ВБВячеслав Александрович Белов
Вячеслав Александрович Белов
SCStanislav V. Chernyavsky
Stanislav V. Chernyavsky
AIAlisher M. Ismailbayev
Alisher M. Ismailbayev
LBLusine R. Baziyants
Lusine R. Baziyants
HighlightsThe article presents the latest data on the techniques of implantation of the mitral homograft in the tricuspid position, and identifies groups of patients who are best suited for this method. Moreover, the article describes the evolution of this type of replacement, and highlights that many surgical techniques, although justified, require further study to show demonstrate their advantages. AbstractDespite the general trend in cardiac surgery towards valve-preserving interventions, valve replacements remain relevant, and the search for the perfect prosthetic valve continues. Many believe that tricuspid valve replacement using a mitral homograft can be the method of choice in certain situations. The analysis of the studies found in the PubMed database led the authors to the following conclusions: most of the data on the use of this technique in patients with infective endocarditis (IE), other indications are congenital heart disease (CHD) and rheumatic heart disease. Patients with IE who have undergone tricuspid valve replacement using a mitral homograft have good medium-term prospects, and respond well to medical treatment of recurrent IE. The mitral homograft in the tricuspid position remains intact even after prosthetic endocarditis. In this regard, it is possible to perform reconstructive intervention in case of prosthetic valve dysfunction without the need for repeated replacement. Such interventions are relevant for patients with growing heart for whom annuloplasty at the first stage of surgery is undesirable. Moreover, it is also cost-effective due to the high cost and low availability of homografts. The possibility of repeated tricuspid valve-in-valve replacement is important for patients who may not survive open surgery. To date, there are not enough long-term and short-term data on using a mitral homograft for tricuspid valve replacement, however, it can be assumed that the results of this technique will be positive provided that the appropriate implantation technique and strict patient selection are ensured. Many authors have come to the conclusion that the optimal homograft implantation technique includes sewing of the graft`s papillary muscles into the wall of the myocardium of the right ventricle (RV), fixating them on the outer surface of the RV, anatomical positioning of the homograft (anterior leaflet faces towards the IVS), and the use of an annuloplasty ring.

18 April 2024 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
RKRoman Komarov
Roman Komarov
DMD.A. Matsuganov
D.A. Matsuganov
MNM D Nuzhdin
M D Nuzhdin
DBD.O. Bystrov
D.O. Bystrov
ADA.O. Danachev
A.O. Danachev
OBJECTIVE To compare the immediate results of mini-thoracotomy and sternotomy in patients with mitral valve disease. MATERIAL AND METHODS The study included 52 patients who underwent mitral valve surgery (25 cases — mini-thoracotomy, 27 cases — sternotomy). RESULTS Aortic cross-clamping time was significantly longer in sternotomy compared to mini-thoracotomy group — 110 vs 94 min (p=0.03). Ventilation time was also significantly longer in the sternotomy group (12 vs. 8 hours, p=0.01). Postoperative morbidity was similar (postoperative wound infection, neurological complications, coronavirus disease, overall in-hospital mortality). CONCLUSION In addition to cosmetic effect, minimally invasive approach in mitral valve surgery has some other advantages including less duration of aortic cross-clamping and mechanical ventilation, availability of reconstructive interventions due to better exposition of the mitral valve and subvalvular structures.

25 June 2023 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
DMDenis A. Matsuganov
Denis A. Matsuganov
МНМихаил Дмитриевич Нуждин
Михаил Дмитриевич Нуждин
HighlightsThe authors have studied anemia`s impact on the long-term mortality after mitral valve surgery. The research results indicate the need to address this modifiable factor in the preoperative period. Aim. To analyze the impact of anemia on the long-term survival of patients after mitral valve surgery.Methods. The study included 103 patients, 46 of them were men, 57 were women. Thirteen patients presented with anemia before surgery, and 90 patients did not have anemia. The survival rate of patients was compared using the Kaplan-Meier estimate.Results. The survival rate after surgery in the group of patients without anemia was higher compared with patients with anemia (p = 0,002). By the end of the follow-up period, the survival rate among patients without anemia reached 50.2%, whereas among patients with anemia it was 0.0%.Conclusion. Anemia is an independent predictor of complications in the postoperative period in patients with low preoperative hemoglobin levels. According to the results, the presence of anemia increases the risk of adverse events by 7.71 times in the preoperative period. Moreover, patients without anemia had the highest (up to 50.2%) survival rate in the long-term period, while patients with anemia had a survival rate equal to 0.0%.